Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LixiLan-O: iGlarLixi vs Glargine vs Lixisenatide in T2DM
NCT02058147Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2014
- Primary completion
- Jun 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
A Phase 3 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Feb 2014; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02058147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058147.